EAU 2017: State of the Art Debate - Evidence for extent of lymphadenectomy in urothelial bladder cancer
London, England (UroToday.com) In this session, Professor Witjes discussed the state of the evidence for lymphadenectomy in bladder cancer. He began by quoting Dr. Skinner who believed that the patients who benefit the most from LND had low volume micrometastic disease.
EAU 2017: Debate - Do we need to follow-up in low grade bladder tumor after 12 months?-Yes (EAU Guidelines)
London, England (UroToday.com) In this session, a debate ensued between two guidelines for the surveillance of low risk bladder tumors. Specifically, what is the best follow-up protocol for low risk tumors that do not recur? Is it 1 year as the NICE guidelines would suggest or 5 years as the EAU guidelines would suggest? Professor Burger was tasked with defending the EAU guideline recommendations of 5 years of total follow-up.
EAU 2017: Perfect adjuvant treatment
London, England (UroToday.com) In this session, Professor Witjes discussed perfect adjuvant treatment for non-muscle invasive bladder cancer. The foundation of any adjuvant treatment planning is a good TUR/re-TUR that allows pathologists to do a proper pathological evaluation.
EAU 2017: Perfect transurethral resection
London, England (UroToday.com) In this session, Professor Babjuk discussed his recommendations for state-of-the-art transurethral resection of bladder tumors (TURBT). At the outset, he recommends considering what one might see prior to the operation. The risk of multiple tumors ranges from 25-37% and the risk of concomitant carcinoma in situ (CIS) is 23-30%. Further, the risk of tumor persistence after initial TURBT is 33-55% and tumor understaging occurs in 1.3-25% of all tumors. These factors should be considered prior to bringing the patient to the operating room.
EAU 2017: Is further screening of Asian men with low baseline prostate-specific antigen levels (≤ 1ng/ml) worthwhile
London, England (UroToday.com) Frequent PSA screening results in considerable increase in detection of incidental and indolent prostate cancers. Current guidelines recommend variable screening intervals for men with PSA levels ≤ 1ng/ml.
EAU 2017: Comparing 20,000 open prostatectomy (RRP) cases to 5,000 robotic prostatectomy (RALP) cases, he noted no differences in oncologic outcome or urinary continence
London, England (UroToday.com) Screening strategies for prostate cancer are changing from a population-wide screening strategy to more selective algorithms that preferentially identify clinically significant prostate cancer. The present study sought to determine the effect of family history of prostate cancer on a population-based screening program.
EAU 2017: Quality of life after robotic, lap, and open surgery: real different?
London, England (UroToday.com) In this session, Dr. Graefen covered differences in robotic versus open surgery at the Martini Klinik in Hamburg, Germany. Comparing 20,000 open prostatectomy (RRP) cases to 5,000 robotic prostatectomy (RALP) cases, he noted no differences in oncologic outcome or urinary continence.